ABSTRACT
Epilepsy originates from unusual electrical rhythm within brain cells, causes seizures. Calotropis species have been utilized to treat a wide spectrum of ailments since antiquity. Despite chemical and biological investigations, there have been minimal studies on their anticonvulsant activity, and the molecular targets of this plant constituents are unexplored. This study aimed to investigate the plausible epileptic targets of Calotropis phytoconstituents through network pharmacology, and to evaluate their binding strength and stability with the identified targets. In detail, 125 phytoconstituents of the Calotropis plant (C. procera and C. gigantea) were assessed for their drug-likeness (DL), blood-brain-barrier (BBB) permeability and oral bioavailability (OB). Network analysis revealed that targets PTGS2 and PPAR-ĆĀ³ were ranked first and fourth, respectively, among the top ten hub genes significantly linked with antiepileptic drug targets. Additionally, docking, molecular dynamic (MD) simulation, and Molecular Mechanics-Poisson-Boltzmann Surface Area (MM-PBSA) were employed to validate the compound-gene interactions. Docking studies suggested ergost-5-en-3-ol, stigmasterol and Ć-sitosterol exhibit stronger binding affinity and favorable interactions than co-crystallized ligands with both the targets. Furthermore, both MD simulations and MM-PBSA calculations substantiated the docking results. Combined data revealed that Calotropis phytoconstituents ergost-5-en-3-ol, stigmasterol, and Ć-sitosterol might be the best inhibitors of both PTGS2 and PPAR-ĆĀ³.
Subject(s)
Anticonvulsants , Calotropis , Cyclooxygenase 2 , Epilepsy , Molecular Docking Simulation , Molecular Dynamics Simulation , Network Pharmacology , PPAR gamma , Anticonvulsants/chemistry , Anticonvulsants/pharmacology , Calotropis/chemistry , Cyclooxygenase 2/metabolism , PPAR gamma/metabolism , Humans , Epilepsy/drug therapy , Epilepsy/metabolism , Phytochemicals/pharmacology , Phytochemicals/chemistry , Phytochemicals/isolation & purification , Blood-Brain Barrier/metabolism , Blood-Brain Barrier/drug effectsABSTRACT
We report the design of a structurally concise alanine derivative (Ala-hyd) that has a rotationally flexible aromatic N-protecting group for alanine and a hydrazide functionality at its carboxylic end. Ala-hyd requires mechanical agitation (physically stirring, vortexing or sonicating) to form supramolecular hydrogels at medium concentrations (0.4-0.8 wt%). At higher concentrations (>0.8 wt%), it spontaneously gelates water on undisturbed cooling of the hot solution, while at lower concentrations (<0.4 wt%), only turbid suspensions were formed upon agitation. In the <0.8 wt% regime, hydrogelation by Ala-hyd is modulated by its concentration as well as by the extent of applied mechanical agitation. Turbidimetry and fluorescence spectroscopy indicate enhanced self-assembly of Ala-hyd upon agitation, and FTIR studies point towards stronger hydrogen bonds in the resulting assemblies. Since Ala-hyd requires mechanical agitation to undergo self-assembly, its aqueous sols exhibited mild shear-thickening behaviour in buffered as well as salt-free conditions. During shearing, the formation of an entangled mesh of long, helical nanofibers coincided with the maximum in the bulk shear viscosity. pH-dependent rheological investigations indicate that protonation of the amine unit (pKa = 8.9) of hydrazide diminishes the self-assembly propensity of this compound. The self-assembly of Ala-hyd can thus be modulated through mechanical as well as chemical cues.
Subject(s)
Alanine/analogs & derivatives , Alanine/chemistry , Hydrogels/chemistry , Water/chemistry , Microscopy, Atomic Force , Microscopy, Electron, Scanning , Nanofibers/chemistry , Nephelometry and Turbidimetry , Rheology , Spectrometry, Fluorescence , Spectroscopy, Fourier Transform InfraredABSTRACT
Water-soluble pro-sensors for acryl compounds including acrylamide (AM) were developed. Spontaneous conversion to active thiolate (Ph-S and Nap-S) occurs through pH-increase. While Ph-S forms flat nano-tapes with AM, Nap-S acted as a turn-on fluorescence detector, sensing AM up to the ppm level.
ABSTRACT
KP1019 comprises a class of ruthenium compounds having promising anticancer activity. Here, we investigated the molecular targets of KP1019 using Saccharomyces cerevisiae as a model organism. Our results revealed that in the absence of the N-terminal tail of histone H3, the growth inhibitory effect of KP1019 was markedly enhanced. Furthermore, H3K56A or rtt109Δ mutants exhibit hypersensitivity for KP1019. Moreover, KP1019 evicts histones from the mononucleosome and interacts specifically with histone H3. We have also shown that KP1019 treatment causes induction of Ribonucleotide Reductase (RNR) genes and degradation of Sml1p. Our results also suggest that DNA damage induced by KP1019 is primarily repaired through double-strand break repair (DSBR). In summary, KP1019 targets histone proteins, with important consequences for DNA damage responses and epigenetics.
Subject(s)
Antineoplastic Agents/pharmacology , DNA Damage , Epigenesis, Genetic/drug effects , Indazoles/pharmacology , Organometallic Compounds/pharmacology , Saccharomyces cerevisiae/drug effects , Chromatin/metabolism , DNA Repair , Drug Screening Assays, Antitumor , G2 Phase Cell Cycle Checkpoints/drug effects , Gene Expression , Gene Expression Regulation, Fungal/drug effects , Histone Deacetylases/metabolism , Histones/metabolism , Humans , Microbial Viability/drug effects , Protein Processing, Post-Translational , Ruthenium Compounds , Saccharomyces cerevisiae/genetics , Saccharomyces cerevisiae Proteins/metabolismABSTRACT
Ruthenium-based anti-cancer drugs have attracted increasing interest in the last 20 years. KP1019 is one of the ruthenium-containing compounds that has demonstrated anti-tumor activity against various cancers, and has been tested in several clinical trials. Despite its success, the mode of action of KP1019 is not well described. In the present study, we have used budding yeast Saccharomyces cerevisiae to elucidate the action of KP1019. We have found that KP1019 causes dose-dependent cell arrest in the S-phase of cell cycle. Furthermore, we have demonstrated for the first time that the yeast mitogen-activated protein (MAP) kinase Hog1 is essential for the cells in response to KP1019. Hog1 is rapidly phosphorylated upon treatment with KP1019, and the deletion of the HOG1 gene potentiates the growth inhibition effect of KP1019. Moreover, we also observed the up-regulation of glycerol-3-phosphate dehydrogenase 1 (GPD1) mRNA in response to KP1019 treatment, a factor that is essential for the hyperosmotic stress response. Our results also reveal that membrane-bound sensor proteins of high osmolarity glycerol (HOG) pathway are crucial for Hog1 phosphorylation in response to KP1019-induced stress. Furthermore, KP1019 has also been found to increase the accumulation of ubiquitinated proteins and deletion of several members of ubiquitination pathways conferred sensitivity for KP1019. The findings presented here strongly suggest the ability of KP1019 to activate Hog1 MAP kinase and induce protein ubiquitination, which may underlie the therapeutic potential of this compound. In summary, we have disclosed a novel mechanism of KP1019 activity.
Subject(s)
Antineoplastic Agents/pharmacology , Indazoles/pharmacology , Mitogen-Activated Protein Kinases/metabolism , Organometallic Compounds/pharmacology , Saccharomyces cerevisiae Proteins/metabolism , Saccharomyces cerevisiae/drug effects , Glycerol-3-Phosphate Dehydrogenase (NAD+)/genetics , Mitogen-Activated Protein Kinases/genetics , Phosphorylation/drug effects , RNA, Messenger/metabolism , Ruthenium Compounds , Saccharomyces cerevisiae/genetics , Saccharomyces cerevisiae/growth & development , Saccharomyces cerevisiae/metabolism , Saccharomyces cerevisiae Proteins/genetics , Ubiquitination/drug effects , Up-RegulationABSTRACT
The majority of the localized drug delivery systems are based on polymeric or polypeptide scaffolds, as weak intermolecular interactions of low molecular weight hydrogelators (LMHGs, Mw <500 Da) are significantly perturbed in the presence of anticancer drugs. Here, we present l-alanine derived low molecular weight hydrogelators (LMHGs) that remain injectable even after entrapping the anticancer drug doxorubicin (DOX). These DOX containing nanoassemblies (DOX-Gel) showed promising anticancer activity in mice models. Subcutaneous injection of DOX-Gel near the tumor achieved a greater decrease in tumour load than by intravenous injection of DOX (DOX-IV), and local injection of DOX alone (DOX-Local) at the tumor site. We noticed that DOX-Gel nanocarriers are especially effective when injected during the early stage of tumor progression, and achieve a substantial decrease in tumor load in the long term.
Subject(s)
Doxorubicin/administration & dosage , Doxorubicin/chemistry , Drug Delivery Systems , Hydrogels/chemistry , Nanoparticles/chemistry , Animals , Cell Line, Tumor , Cell Survival , Coloring Agents/chemistry , Disease Progression , Female , Injections, Intravenous , Mice , Mice, Inbred BALB C , Molecular Weight , Nanotechnology , Neoplasm Transplantation , Neoplasms/drug therapy , Neoplasms/pathology , Polymers/chemistryABSTRACT
Counter polyelectrolytes (PEs) having a degradable polyamide backbone and controlled thiolation are prepared. Their nanosized polyelectrolyte complexes (PECs) spontaneously crosslink under ambient conditions via bioreducible disulfide bonds. These PECs are regenerable after centrifugation, and resist degradation by proteases. They are stable to variations of pH and electrolyte concentration, similar to those encountered in biological milieu. However, they are unraveled in reductive conditions. These PECs act as efficient vectors for delivering entrapped cargo. They entrap with high efficiency, and controllably release, fluorescein isothiocyanate (FITC)-insulin (a model peptide) in vitro. Potent cellular internalization of FITC-insulin within human lung cancer cells with high cell viability is demonstrated.